Alaunos Therapeutics (TCRT) Insider Trading & Ownership $2.74 -0.11 (-3.86%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.78 +0.04 (+1.46%) As of 08/1/2025 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Alaunos Therapeutics (NASDAQ:TCRT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage16.14%Number OfInsiders Buying(Last 3 Years)1Amount OfInsider Buying(Last 3 Years)$487.50KNumber OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$9.51K Get TCRT Insider Trade Alerts Want to know when executives and insiders are buying or selling Alaunos Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address TCRT Insider Buying and Selling by Quarter Alaunos Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/1/2023Kevin S Sr. BoyleCEOSell453$21.00$9,513.00 11/29/2022Robert W PostmaDirectorBuy5,000$97.50$487,500.00 (Data available from 1/1/2013 forward) TCRT Insider Trading Activity - Frequently Asked Questions Who is on Alaunos Therapeutics' Insider Roster? The list of insiders at Alaunos Therapeutics includes Kevin S Sr. Boyle, and Robert W Postma. Learn more on insiders at TCRT. What percentage of Alaunos Therapeutics stock is owned by insiders? 16.14% of Alaunos Therapeutics stock is owned by insiders. Learn more on TCRT's insider holdings. Which Alaunos Therapeutics insiders have been selling company stock? The following insider sold TCRT shares in the last 24 months: Kevin S Sr. Boyle ($9,513.00). How much insider selling is happening at Alaunos Therapeutics? Insiders have sold a total of 453 Alaunos Therapeutics shares in the last 24 months for a total of $9,513.00 sold. Alaunos Therapeutics Key ExecutivesMr. Dale Curtis Hogue Jr. (Age 54)Interim CEO & Director Ms. Melinda Lackey (Age 47)Senior VP of Legal, Administration & Secretary Compensation: $625.12kMr. Michael Wong (Age 44)Vice President of Finance & Principal Accounting Officer More Insider Trading Tools from MarketBeat Related Companies Synlogic Insider Trades Mannatech Insider Trades Lipocine Insider Trades Lexaria Bioscience Insider Trades Cocrystal Pharma Insider Trades Hoth Therapeutics Insider Trades Edesa Biotech Insider Trades MARKER THERAPEUTICS Insider Trades Athira Pharma Insider Trades Minerva Neurosciences Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles The Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months3 Small Caps Drawing Insider and Institutional Support This page (NASDAQ:TCRT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.